CSRxP Applauds Bipartisan Bill To Strengthen Drug Pricing Transparency

May 14, 2019

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today released a statement applauding the introduction of a bill by Senators Chuck Grassley (R-IA) and Richard Durbin (D-IL) that will codify the U.S. Department of Health and Human Services’ (HHS) direct-to-consumer advertising (DTC) rule:

“We applaud Senators Grassley and Durbin for building off of the momentum of last week’s announcement from HHS by taking this step to codify into law greater drug pricing transparency,” said CSRxP executive director Lauren Aronson. “Requiring disclosure of list price information in DTC advertising will shine a light on Big Pharma’s price-gouging and give consumers important information as they discuss the best treatment options with their doctors.”

Last week HHS announced that it finalized a rule to require drug manufacturers to disclose list prices in DTC advertising beginning in July. CSRxP has long supported price transparency as a market-based solution that will help lower prescription drug prices.